Baker BROS. Advisors LP Purchases New Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)

Baker BROS. Advisors LP bought a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 85,500 shares of the company's stock, valued at approximately $3,753,000. Baker BROS. Advisors LP owned 0.15% of Structure Therapeutics at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Sandia Investment Management LP bought a new stake in Structure Therapeutics during the 2nd quarter worth approximately $39,000. Assetmark Inc. boosted its stake in shares of Structure Therapeutics by 120.0% in the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company's stock valued at $58,000 after purchasing an additional 719 shares in the last quarter. Quarry LP purchased a new stake in shares of Structure Therapeutics in the 2nd quarter valued at $79,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Structure Therapeutics by 60.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company's stock valued at $158,000 after purchasing an additional 1,420 shares in the last quarter. Finally, Dearborn Partners LLC purchased a new stake in shares of Structure Therapeutics in the 3rd quarter valued at $202,000. Institutional investors own 91.78% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on GPCR shares. Morgan Stanley started coverage on shares of Structure Therapeutics in a research note on Monday, September 23rd. They issued an "overweight" rating and a $118.00 price objective for the company. JMP Securities cut their price objective on shares of Structure Therapeutics from $91.00 to $86.00 and set a "market outperform" rating for the company in a research note on Friday, August 9th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $65.00 price target on shares of Structure Therapeutics in a research report on Monday, September 23rd. Six analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $86.80.

Structure Therapeutics Price Performance

GPCR traded up $0.68 during trading on Monday, hitting $33.83. 519,135 shares of the stock traded hands, compared to its average volume of 781,662. Structure Therapeutics Inc. has a 12-month low of $26.61 and a 12-month high of $66.38. The firm has a market capitalization of $1.94 billion, a P/E ratio of -46.57 and a beta of -3.23. The firm has a 50-day moving average of $38.21 and a 200 day moving average of $39.45.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.